Barchart Demo Center

Overview

Stocks

Stock Screeners

ETFs

Futures

Funds

Fund Screeners

Foreign Exchange

Sectors

News

Financial Calculators

Embedded Widgets

Portfolio

Screener

JSON Feeds

Symbol Overview

United States|Canada
English|French

Catasys Inc

(NASDAQ: CATS)
Add to Portfolio
+0.67 (+3.94%)
as of Sep 20, 2019

Catasys to Participate in 4th Annual Dougherty &

BusinessWire via COMTEX - Thu Aug 29, 08:30AM EDT
Catasys, Inc. (NASDAQ: CATS) ("Catasys" or the "Company"), a leading AI and technology-enabled healthcare company, today announced that Mr. Terren Peizer, the Company's Chairman and CEO, is scheduled to participate in one-on-one a(full story)
CATS: 17.69 (+0.67), CATSD: 10.0000 (+1.1200)

Catasys Reports 2019 Second Quarter Financial Results

BusinessWire via COMTEX - Wed Aug 14, 04:05PM EDT
Catasys, Inc. (NASDAQ: CATS) ("Catasys" or the "Company"), a leading AI and technology-enabled healthcare company, today reported its financial results for the second quarter ended June 30, 2019. The Company provides big data-base(full story)
CATS: 17.69 (+0.67), CATSD: 10.0000 (+1.1200)

Catasys Expands Partnership with Leading National

BusinessWire via COMTEX - Tue Aug 13, 08:30AM EDT
Catasys, Inc. (NASDAQ: CATS) ("Catasys" or the "Company"), a leading AI and technology-enabled healthcare company, today announced the expansion of its OnTrak-A solution with a leading national health plan into six new states. OnT(full story)
CATS: 17.69 (+0.67), CATSD: 10.0000 (+1.1200)

Catasys Schedules 2019 Second Quarter Financial

BusinessWire via COMTEX - Mon Aug 12, 08:30AM EDT
Catasys, Inc. (NASDAQ: CATS) ("Catasys" or the "Company"), a leading AI and technology-enabled healthcare company, today announced that the Company will be releasing financial results for its second quarter ended June 30, 2019, af(full story)
CATS: 17.69 (+0.67), CATSD: 10.0000 (+1.1200)

BriaCell Appoints Richard J. Berman to Board of

GlobeNewswire via COMTEX - Mon Aug 12, 06:30AM EDT
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, today announced that it has appointed M(full story)
BCTXF: 0.0550 (-0.0074), ADXS: 0.29 (-0.01), IMRN: 2.76 (+0.01), CATS: 17.69 (+0.67), CYRX: 17.66 (-0.11), BCT.VN: 0.065 (-0.015), BIVI: 0.0750 (unch)